Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Regulatory agencies request an assessment of cardiovascular safety for all "new" oral anti-diabetic drugs in order to avoid possible negative effects on cardiovascular events. Dipeptidyl peptidase 4 inhibitors have emerged as a new therapeutic alternative for the treatment of type 2 diabetes mellitus, but the several large post-marketing clinical t...
Alternative Titles
Full title
Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4818902
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4818902
Other Identifiers
ISSN
1475-2840
E-ISSN
1475-2840
DOI
10.1186/s12933-016-0379-4
